IL17A and diabetes mellitus: Since diabetes-mediated IL-17A production is RORγt dependent, and there is a RORγt small molecule inhibitor (SR1001) that can pass the blood-retina-barrier, we postulated that RORγt would be a good therapeutic target and SR1001 would be a good drug candidate for the treatment of diabetic retinopathy.